Head-to-head evidence
9MW1911 vs astegolimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanism: ST2 (IL1RL1) · full Chronic Obstructive Pulmonary Disease pipeline
9MW1911
Developed by Mabwell Bioscience
NCT05803902 · Phase 1 · completed
The study was randomized and blinded with a placebo comparator, but it was conducted in healthy volunteers purely to check safety and dosing rather than to test whether the drug works in patients. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2027 · NCT07292714 (registry estimate)
astegolimab
Developed by Roche
NCT05037929 · Phase 2 · completed
This was a large, randomized, double-blind, placebo-controlled trial in 1,334 patients using exacerbation rate, a direct clinical outcome, as its primary measure. The every-two-weeks dosing arm reduced exacerbations by a statistically significant 15.4% versus placebo over 52 weeks.
Primary endpoint met for the every-two-weeks regimen only (Lancet: 15% reduction, p=0.0494); the every-four-weeks arm was not statistically significant. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: June 2027 · NCT05878769 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: 9MW1911's landscape · astegolimab's landscape